View clinical trials related to Stuttering.
Filter by:The purpose of this research study is to find out the potential benefits and safety of asenapine (Saphris®) in adults who suffer from the developmental form of stuttering. It is hypothesized that individuals who are randomly assigned to asenapine will have an improvement in speech as compared to a placebo.
The purpose of this research project is to test the effects of exposure of different forms of tactile speech feedback on overt stuttering frequency.
Subjects' utterances were submitted to acoustic analysis before and after the intervention program applied on prosodic basis.
A multicenter, randomized, 3 arm, placebo-controlled clinical trial to assess the efficacy, safety and tolerability of pagoclone for adults with stuttering.
This study aims to determine the percentage and predictors of stuttering relapse following treatment with the Lidcombe Program. It will also investigate the effectiveness of sending reminder messages to parents to assist in reducing relapse.
The purpose of this study is to evaluate the efficiency of the Lidcombe Program for early stuttering by varying the time between clinic visits during the first stage of the program.
This is a research study of the investigational drug, Pagoclone, in the treatment of persistent developmental stuttering (PDS), which includes frequent repetitions or prolongations of sounds or syllables or words, or frequent hesitations or pauses that disrupt the flow of speech. Pagoclone is an investigational drug, so it is not approved by the United States Food and Drug Administration.
The objective of the study is to determine the effects of pagoclone on the symptoms of Persistent Developmental Stuttering, using a flexible dosing titration regimen on persistent developmental stuttering in patients 18 to 65 years of age.
The goal of the study is to examine the cortical activity during speech perception and speech production in idiopathic stutterers compared to fluent speakers. Therefore, the noninvasive method of magnetoencephalography (MEG) is used. A better understanding for the complexity of speech perception and its pathology should be developed. Fundamental properties of stuttering are repetitions, prolongations, and blocks. In most cases stuttering emerges between 2 and 5 years of age. The auditory feedback should become less important during development, as soon as information about mispronounced words does not occur anymore. During speech development this control function should be adopted by other systems. In stutterers the dominance of the acoustic control should remain. Brain imaging studies with positron emission tomography (PET) or magnetic resonance imaging (MRI) show defects in the network of motor system, in the lateralization of speech areas, and functions of the auditory cortex. Magnetoencephalographic studies describe a similar variety as cause of stuttering. There may be defects in the auditory feedback, a modification of the lateralization of speech areas, or an alteration of co-action of motor planning and auditory system. The benefit of magnetoencephalography is a very good temporal resolution in the range of milliseconds combined with good spatial resolution. Therefore, it is well suited to examine the dynamics of cortical processing during stuttering. In this study evoked components of the auditory systems related to complex sounds, vocals, consonant-vocal combinations, and single words are analyzed. Differences of these components in the auditory cortices of stutterers and fluent speakers are hypothesized as well in temporal structure as in localization and lateralization.
This study will use positron emission tomography (PET) to examine the role of the chemical messenger dopamine in stuttering. It will measure and compare the number of dopamine receptors and the amount of dopamine released in the brains of stutterers with that of normal volunteers. The results may provide information about how drugs that block dopamine's effect might work to enable fluent speech. Healthy normal volunteers and people with developmental stuttering between the ages of 18 and 55 may be eligible for this study. Candidates will be screened with a medical history and possibly a physical examination and laboratory tests. Participants will have a hearing test and cognitive function tests to measure speech, language, memory and visual skills. In addition, they will undergo the following procedures: - PET scanning to measure brain blood flow and dopamine distribution in the brain. PET uses radioactive materials to show cellular activity in specific tissues of the body. Before starting the procedure, a thin plastic tube (intravenous, or IV line) is placed in a vein in each arm of the subject and a special plastic mask is molded to the face. (The mask is used to insure that the position of the head does not change during the scan.) For the scan, the subject lies on a bed that is positioned into the scanner. A preliminary "transmission" scan is done to make necessary measurements and adjustments. Following this scan, 10 injections of radioactive water are given through an IV line. During these injections, the subject performs a series of speech tasks-such as singing, telling a story, or reciting nursery rhymes-that will elicit either fluent speech or stuttering. A special camera detects the radiation emitted and produces images of brain blood flow during stuttering and normal speech. Next, raclopride (a radioactive material that attaches to dopamine receptors on the cell surface) is given through an IV line and more pictures of the brain are taken. Fifty minutes after the raclopride injection, amphetamine-a drug that increases brain dopamine levels-is injected through the other IV line and more pictures are taken to show dopamine distribution in the brain. Fifty minutes after the amphetamine infusion, the IV lines are removed. - Magnetic resonance imaging (MRI) of the brain to complement and interpret information from the PET scans. MRI uses a strong magnetic field and radio waves to show structural changes in tissues. The subject lies on a table surrounded by a metal cylinder (the scanner). During the procedure, which may take from 20 minutes to 2 hours, subjects may be asked to perform simple tasks, such as speaking or moving their arms. They can speak with a staff member via an intercom at all times during the procedure and can be moved out of the machine any time they request. Participants may be asked to return for up to two scanning sessions within a year. For these scans, only 1 injection of radioactive water will be given.